Search

Purpose: The aim of this study was to evaluate Cyanidin-3-O-β-d-glucopyranoside on improvement and protection for erectile function. Materials and Methods: Sprague-Dawley rats (12wks old) were divided into three groups (n=12 in each): normal control, diabetes (DM), and diabetes with Cyanidin-3-O-β-d-glucopyranoside (C3G) concentration materials treatment (DM＋C3G). DM and DM＋C3G group received a single injection of streptozotocin (50 mg/kg), and 4 wk after induction of diabetes, DM＋C3G group were treated with daily C3G (10 mg/kg) dissolved in water for 8 wk. After 12 wk of streptozotocin injections, rats in each group underwent intracavernosal pressure measurement (ICP) and then the corporal tissues were sampled. Results: DM group showed markedly lower erectile parameters than those in the control group, whereas rats in the DM＋C3G group showed improved erectile function by minimizing corporal apoptosis. Conclusions: The current study is the first to suggest that Cyanidin-3-O-β-d-glucopyranoside may have a potency to improve and protect erectile function in a rat model of diabetic erectile dysfunction.